Sinovac Biotech (SVA) 5.57 $SVA
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
PR Newswire - Fri Jul 25, 4:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company will host a conference call prior to the market opening on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac to supply seasonal flu vaccine Anflu in Beijing in Q3 2014
M2 - Wed Jul 23, 7:07AM CDT
Chinese biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) said on Wednesday that it will supply the seasonal influenza vaccine Anflu in Beijing, beginning in the third quarter of 2014, following authorisation from Beijing Centers for Disease Control and Prevention (Beijing CDC).
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
PR Newswire - Wed Jul 23, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC"
to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014.
Monday’s Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech
Leo Sun, The Motley Fool - Motley Fool - Mon Jul 21, 8:06AM CDT
Let's take a look at three stocks -- Allergan , Anacor Pharmaceuticals , and Sinovac Biotech -- which could all loom large in health care headlines this Monday morning. Allergan tops earnings estimates for the second quarter Allergan...
Sinovac wins CNY16m tender to supply inactivated hepatitis A vaccine Healive in Beijing
M2 - Mon Jul 21, 7:34AM CDT
Biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) reported on Monday that it is the exclusive supplier of inactivated hepatitis A vaccine Healive in pre-filled syringe dosage in Beijing under the Expanded Programme of Immunisation (EPI).
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
PR Newswire - Mon Jul 21, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB. The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months upon the demand.
Sinovac Schedules 2014 Annual Meeting of Shareholders
PR Newswire - Mon Jul 14, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of July 9, 2014 will be eligible to vote and are invited to attend.
Pertussis - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trkkbq/pertussis) has announced the addition of the "Pertussis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pertussis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Beijing Minhai Biotechnology - Beijing Tiantan Biological Products - Bharat Biotech International - Biological E - GlaxoSmithKline - Green Cross - Indian Immunologicals - LG Life Sciences - Novartis - Panacea Biotec - Sanofi - Serum Institute of India - Sinovac Biotech - Synthetic Biologics - Takeda - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/trkkbq/pertussis
Sinovac Announces Favorable Reduction in Value Added Tax Rate
PR Newswire - Wed Jun 25, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT" rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a joint notice on reducing and unifying the value added tax (VAT) rate published by the Ministry of Finance of China and State Administration of Taxation of China. The notification will become effective July 1, 2014.
Simavita Limited Announces Closing of First Tranche of Private Placement Offering
Marketwire - Sun Jun 22, 6:29PM CDT
Simavita Limited ("Simavita" or the "Company" (TSX VENTURE: SV) (ASX: SVA) is pleased to announce that the Company has closed an initial tranche (the "First Tranche" of a private placement (the "Private Placement" , as previously announced on June 18, 2014 in Canada (June 19, 2014 in Australia), to sophisticated and institutional investors in Australia and the United Kingdom.
Simavita Limited Announces Proposed Private Placement and Special Meeting of the Shareholders
Marketwire - Wed Jun 18, 6:43PM CDT
Simavita Limited ("Simavita" or the "Company" (TSX VENTURE: SV)(ASX: SVA) is pleased to announce that, subject to the approval of the TSX Venture Exchange (the "TSXV" and the Australian Securities Exchange (the "ASX" , it is undertaking a private placement (the "Private Placement" to sophisticated and institutional investors in Australia and New Zealand and to accredited investors in Canada and the United States.
Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014: Includes 24 Company Profiles
M2 - Thu May 29, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r33tpd/streptococcus) has announced the addition of the "Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Abera Bioscience AB - Beijing Minhai Biotechnology - Chongqing Zhifei Biological Products - ContraFect Corporation - Dainippon Sumitomo Pharma - Eurocine Vaccines - FluGen - Furiex Pharmaceuticals - Genocea Biosciences - GlaxoSmithKline - GlycoVaxyn - Liquidia Technologies, Inc. - Merck & Co - Mucosis - Nabriva Therapeutics - Panacea Biotec Limited - SK Chemicals - Sanofi Pasteur - Serum Institute of India - Sinovac Biotech - Valneva - Wellstat Vaccines For more information visit http://www.researchandmarkets.com/research/r3...eptococcus
Hand, Foot And Mouth Disease Therapeutics Pipeline Review Report 2014
M2 - Wed May 28, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2drc/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hand, Foot And Mouth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hand, Foot And Mouth Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - CJ CheilJedang Corp. - Sinovac Biotech Ltd. - iQur Ltd. - Chongqing Zhifei Biological Products Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hp...d_foot_and
Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2014
M2 - Wed May 28, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h338v5/haemophilus) has announced the addition of the "Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - LG Life Sciences, Ltd. - Panacea Biotec Limited - Sinovac Biotech Ltd. - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur MSD SNC - Nuron Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/h3...aemophilus
Sinovac reports net income of USD4,000 for Q1 2014
M2 - Thu May 22, 4:20AM CDT
Biopharmaceutical company Sinovac Biotech ( NasdaqGS:SVA) stated on Wednesday that its net income attributable to common stockholders was USD4,000 (USD0.00 per basic and diluted share) for the first quarter ended 31 March 2014.
Sinovac Reports Unaudited First Quarter 2014 Financial Results
PR Newswire - Wed May 21, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2014.
Concise Analysis of the International Human Vaccine Industry
M2 - Tue Mar 25, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfnkh2/china_human) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market. However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each. Key Topics Covered: 1. Overview of Vaccine Industry 2. Overview of China Human Vaccine Industry 3. Human Vaccine Market Segments in China 4. Human Vaccine Import and Export in China 5. Major Human Vaccine Producers in China Companies Mentioned: - Beijing Tiantan Biological Products Co., Ltd. - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd. - Dalian Hissen Bio-Pharm Co., Ltd. - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd. - Sinovac Biotech Ltd. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hf...hina_human
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
PR Newswire - Fri Jul 25, 4:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2014, after market close on Thursday, August 14, 2014 EDT. The Company will host a conference call prior to the market opening on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac to supply seasonal flu vaccine Anflu in Beijing in Q3 2014
M2 - Wed Jul 23, 7:07AM CDT
Chinese biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) said on Wednesday that it will supply the seasonal influenza vaccine Anflu in Beijing, beginning in the third quarter of 2014, following authorisation from Beijing Centers for Disease Control and Prevention (Beijing CDC).
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu
PR Newswire - Wed Jul 23, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention ("Beijing CDC"
to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. Monday’s Top Biotech Stories: Allergan, Anacor, and Sinovac Biotech
Leo Sun, The Motley Fool - Motley Fool - Mon Jul 21, 8:06AM CDT
Let's take a look at three stocks -- Allergan , Anacor Pharmaceuticals , and Sinovac Biotech -- which could all loom large in health care headlines this Monday morning. Allergan tops earnings estimates for the second quarter Allergan...
Sinovac wins CNY16m tender to supply inactivated hepatitis A vaccine Healive in Beijing
M2 - Mon Jul 21, 7:34AM CDT
Biopharmaceutical company Sinovac Biotech (NasdaqGS:SVA) reported on Monday that it is the exclusive supplier of inactivated hepatitis A vaccine Healive in pre-filled syringe dosage in Beijing under the Expanded Programme of Immunisation (EPI).
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
PR Newswire - Mon Jul 21, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB. The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months upon the demand.
Sinovac Schedules 2014 Annual Meeting of Shareholders
PR Newswire - Mon Jul 14, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of July 9, 2014 will be eligible to vote and are invited to attend.
Pertussis - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trkkbq/pertussis) has announced the addition of the "Pertussis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pertussis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Beijing Minhai Biotechnology - Beijing Tiantan Biological Products - Bharat Biotech International - Biological E - GlaxoSmithKline - Green Cross - Indian Immunologicals - LG Life Sciences - Novartis - Panacea Biotec - Sanofi - Serum Institute of India - Sinovac Biotech - Synthetic Biologics - Takeda - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/trkkbq/pertussis
Sinovac Announces Favorable Reduction in Value Added Tax Rate
PR Newswire - Wed Jun 25, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT"
rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a joint notice on reducing and unifying the value added tax (VAT) rate published by the Ministry of Finance of China and State Administration of Taxation of China. The notification will become effective July 1, 2014. Simavita Limited Announces Closing of First Tranche of Private Placement Offering
Marketwire - Sun Jun 22, 6:29PM CDT
Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE: SV) (ASX: SVA) is pleased to announce that the Company has closed an initial tranche (the "First Tranche" of a private placement (the "Private Placement" , as previously announced on June 18, 2014 in Canada (June 19, 2014 in Australia), to sophisticated and institutional investors in Australia and the United Kingdom. Simavita Limited Announces Proposed Private Placement and Special Meeting of the Shareholders
Marketwire - Wed Jun 18, 6:43PM CDT
Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE: SV)(ASX: SVA) is pleased to announce that, subject to the approval of the TSX Venture Exchange (the "TSXV" and the Australian Securities Exchange (the "ASX" , it is undertaking a private placement (the "Private Placement" to sophisticated and institutional investors in Australia and New Zealand and to accredited investors in Canada and the United States. Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014: Includes 24 Company Profiles
M2 - Thu May 29, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r33tpd/streptococcus) has announced the addition of the "Streptococcus Pneumoniae (Pneumococcus) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Abera Bioscience AB - Beijing Minhai Biotechnology - Chongqing Zhifei Biological Products - ContraFect Corporation - Dainippon Sumitomo Pharma - Eurocine Vaccines - FluGen - Furiex Pharmaceuticals - Genocea Biosciences - GlaxoSmithKline - GlycoVaxyn - Liquidia Technologies, Inc. - Merck & Co - Mucosis - Nabriva Therapeutics - Panacea Biotec Limited - SK Chemicals - Sanofi Pasteur - Serum Institute of India - Sinovac Biotech - Valneva - Wellstat Vaccines For more information visit http://www.researchandmarkets.com/research/r3...eptococcus
Hand, Foot And Mouth Disease Therapeutics Pipeline Review Report 2014
M2 - Wed May 28, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2drc/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hand, Foot And Mouth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hand, Foot And Mouth Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - CJ CheilJedang Corp. - Sinovac Biotech Ltd. - iQur Ltd. - Chongqing Zhifei Biological Products Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hp...d_foot_and
Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2014
M2 - Wed May 28, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h338v5/haemophilus) has announced the addition of the "Haemophilus Influenzae Type b Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - LG Life Sciences, Ltd. - Panacea Biotec Limited - Sinovac Biotech Ltd. - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur MSD SNC - Nuron Biotech, Inc. For more information visit http://www.researchandmarkets.com/research/h3...aemophilus
Sinovac reports net income of USD4,000 for Q1 2014
M2 - Thu May 22, 4:20AM CDT
Biopharmaceutical company Sinovac Biotech ( NasdaqGS:SVA) stated on Wednesday that its net income attributable to common stockholders was USD4,000 (USD0.00 per basic and diluted share) for the first quarter ended 31 March 2014.
Sinovac Reports Unaudited First Quarter 2014 Financial Results
PR Newswire - Wed May 21, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2014.
Concise Analysis of the International Human Vaccine Industry
M2 - Tue Mar 25, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfnkh2/china_human) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market. However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each. Key Topics Covered: 1. Overview of Vaccine Industry 2. Overview of China Human Vaccine Industry 3. Human Vaccine Market Segments in China 4. Human Vaccine Import and Export in China 5. Major Human Vaccine Producers in China Companies Mentioned: - Beijing Tiantan Biological Products Co., Ltd. - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd. - Dalian Hissen Bio-Pharm Co., Ltd. - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd. - Sinovac Biotech Ltd. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hf...hina_human
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
